A
Akero Therapeutics D
D
AKRO
46.380
USD
-2.57
(-5.24%)
مغلق
حجم التداول
59,698
الربح لكل سهم
-4
العائد الربحي
-
P/E
-12
حجم السوق
3,697,300,897
الأخبار المقالات
العنوان: Akero Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.